Hormone suppression therapy may harm survival for African-American prostate cancer patients

Androgen-deprivation therapy may shorten survival in African-American men with favourable-risk prostate cancer, researchers say.

X-ray of prostate cancer radiotherapy, or brachytherapy

It is unclear whether androgen-deprivation therapy (ADT) to reduce prostate size prior to radiation therapy (brachytherapy) is beneficial in African-American men with prostate cancer (PCa). 

To explore, researchers carried out a retrospective study looking at 7,252 men with low-risk or favourable intermediate-risk PCa who underwent brachytherapy with (n=1,501) or without neoadjuvant ADT. 

Over a median follow-up of eight years, the risk of all-cause (hazard rati0 [HR]: 1.77) or other-cause mortality (HR: 1.86) was significantly higher among African-American men compared with non-African American men who received ADT. But among men not receiving ADT, mortality risks were comparable between African Americans and non-African Americans. 

Writing in Cancer (online, 4 August 2016)[1]
, the researchers say that ADT may shorten survival in African-American men with favourable-risk PCa, and the treatment should therefore be reserved for African-American men with higher risk disease.

References

[1] Kovtun KA, Chen M-H, Braccioforte MH et al. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. Cancer 2016. doi: 10.1002/cncr.30224

Last updated
Citation
Clinical Pharmacist, CP, September 2016, Vol 8, No 9;8(9):DOI:10.1211/PJ.2016.20201574